Smith & Nephew plc: 2024 Full Year and Q4 Results Summary
Business Context and Reporting Period
This Form 6-K filing, dated February 25, 2025, reports the Fourth Quarter and Full Year 2024 results for Smith & Nephew plc, a global medical technology business. The company operates three primary business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The reporting period covers the year ended December 31, 2024, with a focus on the execution of the company's "12-Point Plan" aimed at driving revenue growth, margin expansion, and cash flow improvement.
Key Financial Metrics (Full Year 2024)
| Metric | 2024 ($m) | 2023 ($m) | Change |
|---|---|---|---|
| Revenue | 5,810 | 5,549 | +4.7% (Reported) / +5.3% (Underlying) |
| Operating Profit | 657 | 425 | +54.6% |
| Operating Profit Margin | 11.3% | 7.7% | +360 bps |
| Trading Profit | 1,049 | 970 | +8.2% |
| Trading Profit Margin | 18.1% | 17.5% | +60 bps |
| EPS (Basic) | 47.2 cents | 30.2 cents | +56.3% |
| EPSA (Adjusted) | 84.3 cents | 82.8 cents | +1.7% |
| Cash from Operations | 1,245 | 829 | +50.2% |
| Free Cash Flow | 551 | 129 | +327.1% |
| Net Debt (excl. leases) | 2,513 | 2,577 | -2.5% |
| Adjusted Leverage Ratio | 1.9x | 2.1x | -0.2x |
Material Changes vs. Prior Period
- Revenue Growth: Underlying revenue grew 5.3% for the full year, driven by operational improvements and new product launches (over 60% of growth from products launched in the last five years). Reported growth was 4.7%, impacted by a -60bps foreign exchange headwind.
- Profitability: Operating profit surged 54.6% to $657 million, primarily due to a significant reduction in restructuring costs ($123 million in 2024 vs. $220 million in 2023) and margin expansion. Trading profit margin improved by 60 basis points to 18.1%.
- Cash Flow: Cash generation improved dramatically. Trading cash conversion rose to 95% (from 65% in 2023), and Free Cash Flow increased to $551 million (from $129 million), driven by working capital discipline and reduced capital expenditure.
- Segment Performance:
- Orthopaedics: Underlying growth of 4.6%. US Reconstruction showed sequential improvement, while China remained a headwind.
- Sports Medicine & ENT: Underlying growth of 6.2%. Strong performance in Sports Medicine Joint Repair (led by REGENETEN) and ENT, offset by China VBP headwinds.
- Advanced Wound Management: Underlying growth of 5.1%, with strong double-digit growth in Bioactives and Devices.
- Restructuring: The company delivered a near 9% net reduction in total workforce over 2023-2024, with over 1,000 role reductions in 2024 alone.
Guidance, Outlook, and Risks
- 2025 Revenue Guidance: Underlying revenue growth expected to be around 5% (reported growth ~4.8%). Q1 2025 underlying growth is expected to be 1-2% due to China headwinds and one fewer trading day, with acceleration expected thereafter.
- 2025 Margin Guidance: Trading profit margin expected to range between 19.0% and 20.0%, with stronger performance in the second half as China impacts reduce and operational savings are realized.
- Cash Flow & Costs: Trading cash conversion expected at 80-90%. Restructuring costs expected to decrease to approximately $45 million in 2025.
- Dividend: Full year dividend of 37.5 cents per share (unchanged from 2023). The company targets a payout ratio of 35-40% of EPSA from 2025 onwards.
- Risks and Contingencies:
- China Headwinds: Volume-Based Procurement (VBP) programs continue to impact Reconstruction and Sports Medicine segments. An additional VBP process in Arthroscopic Enabling Technologies is expected to create a ~$25 million revenue headwind in 2025.
- Legal: Ongoing metal-on-metal hip claims, though provisions were reduced by $28 million in 2024.
- Macroeconomic: Inflation, foreign exchange volatility, and potential global economic downturns affecting healthcare spending.
Key Facts for Investor Verification
- China Exposure: Verify the specific impact of VBP on Q1 2025 revenue, as management forecasts a 1-2% underlying growth rate for the quarter due to these headwinds.
- Margin Sustainability: Confirm the realization of the 19-20% trading profit margin target in 2025, given the offsetting effects of cost savings and inflation.
- Cash Conversion: Monitor the ability to maintain the 80-90% trading cash conversion ratio in 2025, which was a significant improvement in 2024.
- Restructuring Completion: Track the reduction of restructuring costs to the guided $45 million, indicating the winding down of the 12-Point Plan charges.
- Product Pipeline: Assess the commercial uptake of new 2024 and 2025 launches (e.g., CATALYSTEM, AETOS, CORIOGRAPH) which are cited as key growth drivers.